Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin …
to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin …
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
MS Hanna, P Mohan, R Knabb… - Annals of the New …, 2014 - ui.adsabs.harvard.edu
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long‑standing standards of care that include low‑molecular‑weight heparin and warfarin …
to long‑standing standards of care that include low‑molecular‑weight heparin and warfarin …
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
MS Hanna, P Mohan, R Knabb, E Gupta… - Annals of the New York …, 2014 - infona.pl
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin …
to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin …
[PDF][PDF] Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
MS Hanna, P Mohan, R Knabb, E Gupta, C Frost… - academia.edu
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.
MS Hanna, P Mohan, R Knabb, E Gupta… - Annals of the New …, 2014 - europepmc.org
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
MS Hanna, P Mohan, R Knabb… - Annals of the New …, 2014 - pubmed.ncbi.nlm.nih.gov
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
[PDF][PDF] Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
MS Hanna, P Mohan, R Knabb, E Gupta, C Frost… - scienceopen.com
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
[PDF][PDF] Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
MS Hanna, P Mohan, R Knabb, E Gupta, C Frost… - Citeseer
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long-standing standards of care that include low-molecular-weight heparin and warfarin …
to long-standing standards of care that include low-molecular-weight heparin and warfarin …